GW Pharmaceuticals PLC operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares GW Pharmaceuticals PLC with three other
companies in this sector in the United Kingdom:
sales of £5.06 million [US$6.18 million]
of which 40%
was Preclinical Research services),
(£5.52 million [US$6.74 million]
(£12.03 million [US$14.69 million]
of which 67%
GW Pharmaceuticals PLC reported sales of £10.32 million (US$12.59 million)
September of 2016.
decrease of 63.9%
versus 2015, when the company's sales were £28.54 million.
Contributing to the drop in overall sales was the 84.3% decline
in Sativex R&d, from £22.28 million to £3.50 million.
There were also decreases in sales in
Pipeline R&d (down 37.0% to £337,000.00 )
However, these declines were partially offset by the increase in sales of
Commercial (up 13.1% to £6.48 million)